New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding: A Systematic Review and Meta-analysis
Top Cited Papers
- 1 July 2013
- journal article
- editorial
- Published by Elsevier BV in Gastroenterology
- Vol. 145 (1), 105-112.e15
- https://doi.org/10.1053/j.gastro.2013.02.041
Abstract
No abstract availableThis publication has 77 references indexed in Scilit:
- A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancerJournal of Thrombosis and Haemostasis, 2012
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary EmbolismThe New England Journal of Medicine, 2012
- Rivaroxaban in Patients with a Recent Acute Coronary SyndromeThe New England Journal of Medicine, 2012
- Low Doses of Acetylsalicylic Acid Increase Risk of Gastrointestinal Bleeding in a Meta-AnalysisClinical Gastroenterology and Hepatology, 2011
- Rationale and design of the Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndromeAmerican Heart Journal, 2011
- Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trialEuropean Heart Journal, 2011
- The potential role of new oral anticoagulants in the prevention and treatment of thromboembolismPharmacology & Therapeutics, 2011
- New AnticoagulantsCirculation, 2010
- Apixaban or Enoxaparin for Thromboprophylaxis after Knee ReplacementThe New England Journal of Medicine, 2009
- Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control studyBMJ, 2006